biostudies-literatureUnknown6(17)Styczen H<h4>Objective</h4>In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.<h4>Patients and methods</h4>Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.<h4>Results</h4>Positivity of HER-2 status (IHC score 2+/ISH+ andOncotarget15065-76https://www.ebi.ac.uk/biostudies/studies/S-EPMC4558136biostudies-literatureHER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.PMC4558136Styczen HSprenger TConradi LCGhadimi BMBeissbarth TRuschoff JNagelmeier IStanek KBoczek UNietert MMiddel PLiersch THomayounfar KWolff HAKitz JfalseHER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.<h4>Objective</h4>In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.<h4>Patients and methods</h4>Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.<h4>Results</h4>Positivity of HER-2 status (IHC score 2+/ISH+ and2015-01-01T00:00:00Z2015 Jun2026-05-30T13:37:52.297Z2019-03-27T01:57:44ZS-EPMC45581362591515510.18632/oncotarget.3527